Post-transplant Cyclophosphamide is a Valid Option for GVHD Prophylaxis in Both HLA-matched and Mismatched Allogeneic Transplants

Main Article Content

Nahla A. M. Hamed
Dalia A. Nafea
Essam A. Abdel-Mohsen
Omar M. Ghalab
Abdel-Salam A. Adam

Abstract

Despite improvement in transplantation techniques and supportive care, graft versus host disease (GVHD) remains a major cause of post-transplant morbidity and mortality. Advances in immunosuppressive regimens have reduced the incidence and severity of acute GVHD; with no such impact on chronic GVHD. In addition to the considerable toxicity of calcineurin inhibitors (CNI)-based regimens [1]. We compared the safety and efficacy of post allogeneic transplant cyclophosphamide as GVHD prophylaxis versus CNI prophylaxis. This study included 63 patients (2 groups) admitted to Hematology unit, Maadi Armed Forces Medical Compound, Cairo for allogeneic stem cell transplantation for hematological malignancies. Group I received post-transplant cyclophosphamide prophylaxis (50 mg /kg/day), while group II received CNI based prophylaxis. Patients were followed for 6 months for acute and chronic GVHD, infections, and drug toxicities. Most patients successfully underwent hematopoietic reconstitution with no significant difference between both groups in time to hematological recovery. Hepatic and renal toxicities were more common in group II than group I (78.6% vs. 30.8%, P=0.002) and (60% vs. 20.5%, P=0.022) respectively. No significant difference between both groups in the incidence of CMV reactivation or acute and chronic GVHD. Disease free survival and overall survival were not significantly different between both groups either in matched or mismatched transplants, with a trend for better survival in group I than group II (4 vs. 1.4 months, P=0.087). We concluded that post-transplant cyclophosphamide for GVHD prophylaxis is safe, effective and valid option in allogeneic stem cell transplantation, with a different toxicity profile compared with CNI regimens [2].

Keywords:
Cyclophosphamide, allogeneic stem cell transplantation, GVHD

Article Details

How to Cite
Hamed, N. A. M., Nafea, D. A., Abdel-Mohsen, E. A., Ghalab, O. M., & Adam, A.-S. A. (2019). Post-transplant Cyclophosphamide is a Valid Option for GVHD Prophylaxis in Both HLA-matched and Mismatched Allogeneic Transplants. Asian Hematology Research Journal, 2(2), 1-9. Retrieved from http://journalahrj.com/index.php/AHRJ/article/view/30105
Section
Original Research Article

References

Little MT, Storb R. History of haematopoietic stem-cell transplantation. Nat Rev Cancer. 2002;2:231–8.

Luznik L, Fuchs EJ. High-dose post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. Immunol Res. 2010;47:65–77.

Storb R, Antin JH, Cutler C. Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease? Biol Blood Marrow Transplant. 2010;16:S18–S27.

Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat. Rev. Immunol. 2012;12:443–458.

Strasser SI, Shulman HM, Flowers ME, et al. Chronic graft-vs-host disease of the liver: Presentation as an acute hepatitis. Hepatology. 2000;32:1265–1271.

Parikh CR, McSweeney PA, Korular D, et al. Renal dysfunction in allogeneic hematopoietic cell transplantation. Kidney Int. 2002;62:566–573.

Jacoby E, Chen A, Loeb DM, et al. Single-agent post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis after human leukocyte antigenematched related bone marrow transplantation for pediatric and young adult patients with hematologic malignancies. Biol Blood Marrow Transplant. 2016;22:112-118.

Luznik L, Bolaños-Meade J, Zahurak M, et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010;115:3224-3230.

Li Y, Li XC, Zheng XX, et al. Blocking both signal 1 and signal 2 of T cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med. 1999;5:1298-1302.

Fischer AC, Ruvolo PP, Burt R, et al. Characterization of the autoreactive T cell repertoire in cyclosporin-induced syngeneic graft-versus-host disease. A highly conserved repertoire mediates autoaggression. J Immunol. 1995;154: 3713-3725.

Beschorner WE, Hess AD, Shinn CA, Santos GW. Transfer of cyclosporine-associated syngeneic graft-versus-host disease by thymocytes. Resemblance to chronic graft-versus-host disease. Transplantation. 1988;45:209-215.

Jenkins MK, Schwartz RH, Pardoll DM. Effects of cyclosporine A on T cell development and clonal deletion. Science. 1988;24:1655-1658.

Kanakry CG, O’Donnell P, Furlong T, et al. Post-transplantation cyclophosphamide following busulfan and fludarabine myeloablative conditioning prevents severe acute and chronic graft-versus-host disease and minimizes duration of immunosuppression: Results of a multi-institutional trial in patients with high-risk hematologic malignancies. Blood. 2013;122:3310.

Alousi AM, Saliba RM, Chen J, et al. A matched controlled analysis of post-transplant cyclophosphamide (CY) versus tacrolimus and minidose methotrexate in matched sibling and unrelated donor transplant recipients receiving reduced-intensity conditioning: post transplant CY is associated with higher rates of acute GVHD. Blood. 2012;120:4200.

Bradstock KF, Bilmon I, Kwan J, et al. Single-agent high-dose cyclophosphamide for graft-versus-host disease prophylaxis in human leukocyte antigen-matched reduced-intensity peripheral blood stem cell transplantation results in an unacceptably high rate of severe acute graft-versus-host disease. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2015;21:941–944.

Alousi AM, Brammer JE, Saliba RM, et al. Phase ii trial of graft versus- host disease prophylaxis with post-transplantation cyclophosphamide after reduced-intensity busulfan/fludarabine conditioning for hematological malignancies. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2015;21:906–912.

Bashey A, Zhang X, Sizemore CA, et al. T-cellereplete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol. 2013;31:1310-1316.

Kanda Y, Chiba S, Hirai H, et al. Allogeneic hematopoietic stem cell transplantation from family members other than HLA identical siblings over the last decade (1991-2000). Blood. 2003;102: 1541-1547.

Petersdorf EW, Gooley TA, Anasetti C, et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood. 1998;92:3515-3520.

Morishima Y, Yabe T, Matsuo K, et al. Effects of HLA allele and killer immunoglobulin-like receptor ligand matching on clinical outcome in leukemia patients undergoing transplantation with T cell-replete marrow from an unrelated donor. Biol Blood Marrow Transplant. 2007;13:315-328.

Kasamon YL, Luznik L, Leffell MS, et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose post transplantation cyclophosphamide: Effect of HLA disparity on outcome. Biol Blood Marrow Transplant. 2010;16:482-489.